Anamorelin: Phase III data

The double-blind, international Phase III ROMANA 1 trial in 477 non-small cell lung cancer (NSCLC) patients with cachexia showed that once-daily 100 mg anamorelin met the co-primary endpoint of increasing median

Read the full 318 word article

How to gain access

Continue reading with a
two-week free trial.